Scarica l'app Stockscreener
29.34
3.31%
0.94
Dopo l'orario di chiusura:
29.34
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché AKRO Giù?
Forum
Previsione
Akero Therapeutics Inc Borsa (AKRO) Ultime notizie
Akero Therapeutics' senior VP Patrick Lamy sells $29,130 in stock By Investing.com - Investing.com Australia
Akero Therapeutics' senior VP Patrick Lamy sells $29,130 in stock - Investing.com India
Insider Selling: Akero Therapeutics, Inc. (NASDAQ:AKRO) VP Sells 1,000 Shares of Stock - MarketBeat
Catriona Yale Sells 9,074 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) Stock - MarketBeat
Akero Therapeutics chief scientific officer sells $118,172 in stock By Investing.com - Investing.com South Africa
Akero Therapeutics executive sells $264k in stock By Investing.com - Investing.com Canada
Akero Therapeutics chief scientific officer sells $118,172 in stock - Investing.com
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Akero Therapeutics, Inc. (AKRO) And Encourages Stockholders to Reach Out - AccessWire
Akero Therapeutics (NASDAQ:AKRO) Trading Down 4.1%What's Next? - MarketBeat
State Street Corp Has $71.81 Million Stock Holdings in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Fmr LLC Purchases 26,691 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Akero Therapeutics (NASDAQ:AKRO) Shares Up 3.5%Here's What Happened - MarketBeat
AKERO THERAPEUTICS INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Akero Therapeutics, Inc.AKRO - The Eastern Progress Online
Bronstein, Gewirtz & Grossman, LLC Is Investigating Akero Therapeutics, Inc. (AKRO) And Encourages Stockholders to Connect - AccessWire
Akero Therapeutics, Inc. (NASDAQ:AKRO) Short Interest Down 9.1% in November - MarketBeat
Akero Therapeutics' chief development officer sells $86,519 in stock By Investing.com - Investing.com South Africa
Akero Therapeutics chief scientific officer sells $148,933 in shares By Investing.com - Investing.com Canada
Akero Therapeutics COO sells shares worth $77,067 - Investing.com India
Akero Therapeutics COO sells shares worth $77,067 By Investing.com - Investing.com South Africa
Akero Therapeutics executive sells $28,480 in common stock By Investing.com - Investing.com South Africa
Akero Therapeutics CFO sells $86,735 in stock By Investing.com - Investing.com Canada
Akero Therapeutics CFO sells $86,735 in stock - Investing.com
Akero Therapeutics' chief development officer sells $86,519 in stock - Investing.com
(AKRO) Technical Data - Stock Traders Daily
Akero Therapeutics, Inc. (AKRO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - AccessWire
Wellington Management Group LLP Purchases 2,782,029 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Charles Schwab Investment Management Inc. Sells 22,269 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
RTW Investments LP Purchases 487,450 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Redmile Group LLC Sells 226,994 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Point72 Asset Management L.P. Acquires Shares of 1,303,323 Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Akero therapeutics COO Jonathan Young sells $321,310 in stock By Investing.com - Investing.com Canada
Akero Therapeutics CEO Andrew Cheng sells $802,250 in shares By Investing.com - Investing.com Nigeria
Akero Therapeutics CEO Andrew Cheng sells $802,250 in shares - Investing.com India
Akero therapeutics COO Jonathan Young sells $321,310 in stock - Investing.com
Why Is Akero Therapeutics, Inc. (AKRO) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds? - Insider Monkey
Janus Henderson Group PLC Buys 201,225 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Cinctive Capital Management LP Buys Shares of 65,307 Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Erste Asset Management GmbH Purchases New Position in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Liver Cirrhosis Market Key Trends, Leading Players, and Future - openPR
Intech Investment Management LLC Takes Position in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Akero Therapeutics, Inc. (NASDAQ:AKRO) Shares Acquired by Fred Alger Management LLC - MarketBeat
Akero Therapeutics, Inc. (NASDAQ:AKRO) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Connor Clark & Lunn Investment Management Ltd. Reduces Position in Akero Therapeutics, Inc. (NASDAQ:AKRO) - Defense World
Connor Clark & Lunn Investment Management Ltd. Trims Holdings in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Akero Therapeutics, Inc. (NASDAQ:AKRO) Stake Boosted by Propel Bio Management LLC - MarketBeat
Akero Therapeutics to Present at the 7th Annual Evercore ISI HealthCONx Conference - The Manila Times
Non-alcoholic Steatohepatitis (NASH) Treatment Market 2032: Clinical Trials, Medication, EMA, PDMA, FDA Approvals, Epidemiology, Therapies, Companies by DelveInsight - The Globe and Mail
How To Trade (AKRO) - Stock Traders Daily
NASH Updates: Boston Pharma, Viking Line Up As Serious Competitors - Citeline News & Insights
Akero Therapeutics' chief development officer sells $251,274 in stock - Investing.com India
Citigroup Initiates Coverage of Akero Therapeutics (AKRO) with Buy Recommendation - MSN
Inventiva Getting Back On Track In NASH Development - Citeline
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):